Vimarsana
Biggest News Aggregation in the World

Page 3 - Genuity Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genuity Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genuity Science Today - Breaking & Trending Today

Bids sought for new power plants, €46m for Fingal flats, and Genuity sale raises questions - Vimarsana News

Bids sought for new power plants, €46m for Fingal flats, and Genuity sale raises questions

Business Today: the best news, analysis and comment from The Irish Times business desk

Government investment in DNA-collecting company Genuity Science loses value - Vimarsana News

Government investment in DNA-collecting company Genuity Science loses value

The Ireland Strategic Investment Fund had invested €66m in the private genetics company acquired in a deal announced yesterday.

DNA collection company Genuity Science acquired in an all-stock deal - Vimarsana News

DNA collection company Genuity Science acquired in an all-stock deal

State’s Isif fund says value of its stake has been impacted by pandemic and other factors

Genuity says Irish DNA database will still be managed locally following sale - Vimarsana News

Genuity says Irish DNA database will still be managed locally following sale

State’s Isif fund says value of its stake has been impacted by pandemic and other factors

BioSpace Movers & Shakers, July 2 - Vimarsana News

BioSpace Movers & Shakers, July 2

Published: Jul 02, 2021 By Alex Keown OcuTerra Therapeutics – David J. Tanzer was named Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs for Boston-based OcuTerra. Prior to joining OcuTerra, Tanzer served as Global Executive Medical Director in the Novartis ophthalmology franchise. Before that, he served as the CMO at Abbott Medical Optics. He also led the Navy Refractive Surgery Program in San Diego, participating as principal or co-investigator in over 50 clinical studies. Delix Therapeutics – David E. Olson, co-founder and Chief Scientific Office...